Valuation: Eyenovia, Inc.

Capitalization 10.09M 9.62M 8.96M 7.94M 14.31M 856M 15.8M 111M 41.08M 352M 37.9M 37.05M 1.54B P/E ratio 2024 *
-0.15x
P/E ratio 2025 * -0.21x
Enterprise value 10.09M 9.62M 8.96M 7.94M 14.31M 856M 15.8M 111M 41.08M 352M 37.9M 37.05M 1.54B EV / Sales 2024 *
11.7x
EV / Sales 2025 * 2.31x
Free-Float
79.61%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-5.80%
1 week-10.33%
Current month-11.41%
1 month-81.11%
3 months-84.42%
6 months-87.29%
Current year-95.78%
More quotes
1 week
0.08
Extreme 0.0845
0.13
1 month
0.08
Extreme 0.079
0.49
Current year
0.08
Extreme 0.079
2.57
1 year
0.08
Extreme 0.079
2.57
3 years
0.08
Extreme 0.079
5.85
5 years
0.08
Extreme 0.079
7.72
10 years
0.08
Extreme 0.079
10.74
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2022-07-31
Chief Tech/Sci/R&D Officer - 2022-12-31
Chief Operating Officer 43 2022-07-17
Manager TitleAgeSince
Chairman 50 2022-02-06
Director/Board Member 64 2018-03-25
Director/Board Member 62 2022-07-31
More insiders
Name Weight AuM 1st Jan change Investor Rating
0.00% 293,477 M€ +34.85% -
More ETFs: Eyenovia, Inc.
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-5.80%-10.33%-95.11%-97.67%10.09M
-1.72%-5.72%+33.95%+220.45%717B
-0.73%+0.58%+17.23%+108.92%492B
-0.27%-2.81%-5.69%-11.63%353B
-0.68%-1.85%+14.51%+38.03%308B
+1.50%-0.12%-2.99%+39.42%252B
-0.16%+0.71%+0.47%-32.23%232B
+0.28%+0.84%+4.68%+28.99%208B
+0.14%-2.26%+2.90%+17.95%199B
+0.24%-1.51%+0.71%+29.95%147B
Average -0.55%-1.48%-2.93%+34.22% 290.86B
Weighted average by Cap. -0.02%-1.45%+12.47%+81.02%
See all sector performances

Financials

2024 *2025 *
Net sales 863K 823K 767K 679K 1.22M 73.24M 1.35M 9.48M 3.51M 30.11M 3.24M 3.17M 131M 4.37M 4.17M 3.88M 3.44M 6.2M 371M 6.84M 47.99M 17.79M 152M 16.42M 16.05M 665M
Net income -37.5M -35.75M -33.31M -29.52M -53.2M -3.18B -58.75M -412M -153M -1.31B -141M -138M -5.71B -34.51M -32.9M -30.66M -27.17M -48.96M -2.93B -54.07M -379M -141M -1.2B -130M -127M -5.25B
Net Debt - -
More financial data * Estimated data
Logo Eyenovia, Inc.
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
Employees
57
More about the company
Date Price Change Volume
24-12-12 0.0877 $ -5.80% 7,578,600
24-12-11 0.0931 $ -6.15% 13,173,460
24-12-10 0.0992 $ +1.12% 74,036,116
24-12-09 0.0981 $ +11.86% 13,108,754
24-12-06 0.0877 $ -9.49% 9,085,050

Delayed Quote Nasdaq, December 12, 2024 at 04:00 pm EST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
surperformance-ratings-light-chart EYENOVIA-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.0931USD
Average target price
3.500USD
Spread / Average Target
+3,659.40%
Consensus

Quarterly revenue - Rate of surprise